APG Asset Management US Inc. Sells 2,103 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

APG Asset Management US Inc. lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,807 shares of the biopharmaceutical company’s stock after selling 2,103 shares during the quarter. APG Asset Management US Inc.’s holdings in Alnylam Pharmaceuticals were worth $8,226,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. AQR Capital Management LLC raised its position in Alnylam Pharmaceuticals by 92.5% in the 2nd quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock worth $65,862,000 after purchasing an additional 130,482 shares during the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its stake in shares of Alnylam Pharmaceuticals by 61.6% in the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 24,217 shares of the biopharmaceutical company’s stock valued at $5,885,000 after buying an additional 9,234 shares during the period. Tri Locum Partners LP acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $10,935,000. Xponance Inc. raised its position in shares of Alnylam Pharmaceuticals by 7.0% during the second quarter. Xponance Inc. now owns 21,076 shares of the biopharmaceutical company’s stock worth $5,121,000 after acquiring an additional 1,378 shares during the last quarter. Finally, Avoro Capital Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 33.3% during the second quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $97,200,000 after acquiring an additional 100,000 shares during the period. 92.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ALNY has been the subject of a number of research reports. Cantor Fitzgerald reiterated a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, September 9th. Stifel Nicolaus lifted their price target on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. UBS Group increased their price objective on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a report on Friday, June 28th. Canaccord Genuity Group lifted their target price on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, Wells Fargo & Company increased their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. Seven investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $279.14.

Alnylam Pharmaceuticals Stock Up 0.7 %

Shares of NASDAQ:ALNY opened at $274.57 on Friday. The firm has a market cap of $34.73 billion, a price-to-earnings ratio of -102.45 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $287.55. The company’s fifty day simple moving average is $262.26 and its 200 day simple moving average is $202.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The business’s revenue for the quarter was up 107.0% on a year-over-year basis. During the same quarter last year, the firm earned ($2.21) earnings per share. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at $20,563,480. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now directly owns 136 shares of the company’s stock, valued at $35,632. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. The disclosure for this sale can be found here. Insiders sold a total of 57,491 shares of company stock valued at $15,446,733 in the last quarter. 1.50% of the stock is currently owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.